Class of 2016
- Year 2016 - Year 3
- From Baltimore, Maryland
- Website www.pathovax.com
PathoVax is a biotech start-up from Johns Hopkins commercializing RGVax, the world’s first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant types. Current vaccines target some cancer-causing HPVs and only focus on sexual transmitted types, resulting in low uptake due to the incomplete coverage and social stigma. Established animal studies have confirmed RGVax’s protection against all 15 oncogenic types and the added coverage against skin HPVs positions RGVax as a childhood vaccine, allowing unrivalled early market entry in a segment with superior uptake.
Weijie Poh: We love challenges.
WP: No one ever again receives an HPV-related cancer diagnosis
WP: We eat! We love good food.
WP: Constantly meeting people who are smarter and more experienced, and then getting them excited in PathoVax.